Osimertinib in patients with T790M mutation-positive, advanced non-small cell lung cancer: Long-term follow-up from a pooled analysis of 2 phase 2 studies.
Myung-Ju AhnChun-Ming TsaiFrances A ShepherdLyudmila BazhenovaLecia V SequistToyoaki HidaJames C H YangSuresh R RamalingamTetsuya MitsudomiPasi A JänneHelen MannMireille CantariniGlenwood D GossPublished in: Cancer (2018)
This pooled analysis represents the most mature clinical trial data for osimertinib in patients with pretreated, T790M-positive, advanced non-small cell lung cancer, further establishing osimertinib as a standard of care for this patient population.
Keyphrases
- advanced non small cell lung cancer
- epidermal growth factor receptor
- clinical trial
- healthcare
- palliative care
- electronic health record
- tyrosine kinase
- case report
- quality improvement
- phase iii
- small cell lung cancer
- study protocol
- big data
- pain management
- open label
- randomized controlled trial
- phase ii
- affordable care act
- machine learning
- case control